All News

The Changing Treatment Landscape for Acute Migraine

September 18, 2020

David Dodick, MD, reviews changes to the treatment landscape for acute migraine.

Sumifilam Improves Multiple Alzheimer Disease Biomarkers in Phase 2b Study

September 17, 2020

The results point to the potential for sumifilam to become a transformative treatment for patients with Alzheimer disease.

Stewart Factor, MD: Long-Term Data on Apomorphine Sublingual Film in Parkinson

September 17, 2020

The director of the Movement Disorders Program and Vance Lanier Chair of Neurology at Emory University School of Medicine gave his perspective on the interim findings of a long-term safety study of apomorphine sublingual film.

Addressing Loneliness and Social Isolation in Patients With Parkinson Disease

September 17, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.

Satralizumab Reduces Risk of Relapse, Including in Treatment-Naïve NMOSD

September 17, 2020

Two posters presented at MDS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.

Joaquim Ferreria, MD, PhD: Opicapone’s Use in Levodopa-Treated Patients With Parkinson Disease

September 16, 2020

The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.

Apomorphine Sublingual Film Shows Long-Term Efficacy in OFF Episode Treatment

September 16, 2020

The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.

THN102 Is Safe, Improves Excessive Daytime Sleepiness in Parkinson Disease

September 16, 2020

The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.

Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MS

September 16, 2020

The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.

Neurology Residency Training During a Pandemic

September 16, 2020

In part 2 of this interview, Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, describes how her resident program experience was impacted by the pandemic.

Mary Schroth, MD: Cure SMA’s Ongoing Advocacy Initiatives

September 15, 2020

The chief medical officer at Cure SMA spoke to the ongoing work that the organization does in advocating for patients with spinal muscular atrophy, particularly for newborn screening.

Amantadine Shows Treatment Durability for Reducing OFF Time in Parkinson Disease

September 15, 2020

The percentage of patients reporting no OFF time and no impact of OFF on daily function more than doubled by the first on-treatment visit in this open-label trial.

Indu Subramanian, MD: The Effect of Loneliness on Parkinson Disease Severity

September 15, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education and Clinical Centers discussed how loneliness can impact Parkinson disease severity and how holistic approaches to care may help.

Tau Levels May Predict Early Disability, Worse Prognosis in MS

September 15, 2020

Data show that higher CSF tau levels at diagnosis correlated with worse disability independent of age, though no such associations were identified with amyloid-beta.

Levodopa-Carbidopa Intestinal Gel Superior to Immediate Release Capsules for ON Time Without Dyskinesia

September 15, 2020

Benefits of levodopa-carbidopa intestinal gel lasted throughout the day and showed greater benefits of continuous dopaminergic stimulation in disease control than immediate release oral capsules.

Opicapone Improves ON, OFF Time in Levodopa-Treated Patients With Parkinson Disease

September 14, 2020

The COMT inhibitor, which was approved in April 2020, may be a worthwhile option as a first-line adjunctive treatment for those with Parkinson disease with motor fluctuations.

Rapid Readout: Expert Perspectives on Multiple Sclerosis - Data from the 8th Joint ACTRIMS-ECTRIMS Meeting 2020

September 14, 2020

Experts in multiple sclerosis review top data presented at the 8th joint ACTRIMS-ECTRIMS meeting.

Levodopa-Carbidopa Intestinal Gel Effective for Dyskinesia in Advanced Parkinson Disease

September 14, 2020

Improvement in dyskinesia occurred after 2 weeks of treatment with levodopa-carbidopa intestinal gel and was sustained throughout the study.

Dravet Syndrome Foundation to Host Virtual Workshop

September 14, 2020

Day of Dravet, a 1-day virtual event on Saturday, October 17th will give attendees an opportunity to meet industry representatives and ask questions.

Ponesimod Linked to Low Levels of Disease Activity in Relapsing Multiple Sclerosis

September 14, 2020

No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.